Qiagen (NYSE:QGEN) Stock Gets Downgrade from Barclays

Qiagen (NYSE:QGEN) was downgraded by equities researchers at Barclays from an “overweight” rating to an “equal weight” rating in a research note issued on Wednesday, Benzinga reports. They presently have a $53.00 price objective on the stock, down from their prior price objective of $55.00. Barclays‘s target price would suggest a potential upside of 5.57% from the company’s current price.

QGEN has been the subject of a number of other research reports. DZ Bank downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Robert W. Baird increased their price target on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Weiss Ratings raised shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 11th. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a report on Friday, August 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Qiagen in a research note on Friday, September 11th. Four investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average target price of $46.09.

Qiagen Trading Down 0.3%

NYSE QGEN opened at $50.20 on Wednesday. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The company’s 50 day simple moving average is $44.73 and its two-hundred day simple moving average is $42.70.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the previous year, the firm posted $0.60 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts predict that Qiagen will post 2.44 EPS for the current year.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently bought and sold shares of the stock. Amundi lifted its position in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after purchasing an additional 524,959 shares during the last quarter. State Street Corp grew its holdings in shares of Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company’s stock worth $85,363,000 after purchasing an additional 93,575 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Qiagen by 20.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock worth $66,649,000 after purchasing an additional 286,665 shares during the last quarter. Swiss National Bank grew its holdings in shares of Qiagen by 21.1% in the first quarter. Swiss National Bank now owns 716,059 shares of the company’s stock worth $28,686,000 after purchasing an additional 124,920 shares during the last quarter. Finally, Arbejdsmarkedets Tillaegspension increased its stake in shares of Qiagen by 24.8% in the first quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company’s stock worth $25,502,000 after buying an additional 126,405 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.